{"transactions":[{"id":924552,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T16:30:10.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":145000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":145000,"derivative":{"exercise_price":0.44,"expiration_date":"2036-02-01","underlying":"American Depository Shares","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0001193125-26-033754","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000119312526033754/ownership.xml","form_type":"4"}},{"id":924551,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T16:30:10.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":46637,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":46637,"derivative":{"exercise_price":1,"expiration_date":"2036-02-01","underlying":"American Depository Shares","underlying_shares":46637},"source":{"system":"sec-edgar","filing":"0001193125-26-033754","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000119312526033754/ownership.xml","form_type":"4"}},{"id":924550,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T16:30:10.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":139913,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":139913,"derivative":{"exercise_price":0.44,"expiration_date":"2036-02-01","underlying":"American Depositary Shares","underlying_shares":139913},"source":{"system":"sec-edgar","filing":"0001193125-26-033754","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000119312526033754/ownership.xml","form_type":"4"}},{"id":1292838,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Share Options (Right to buy)","published_at":"2025-01-28T16:05:15.000Z","date":"2025-01-25","kind":"grant","planned":false,"acquired":true,"shares":116000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on January 25, 2026, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":116000,"derivative":{"exercise_price":2.91,"expiration_date":"2035-01-25","underlying":"American Depository Shares","underlying_shares":116000},"source":{"system":"sec-edgar","filing":"0000950170-25-009794","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000095017025009794/ownership.xml","form_type":"4"}},{"id":1406424,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-16T20:49:03.000Z","date":"2024-09-13","kind":"sale","planned":false,"acquired":false,"shares":10937,"price":4.221,"value":46165.077,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.01 to $4.43, inclusive."}],"balance_after":78630,"source":{"system":"sec-edgar","filing":"0000950170-24-106974","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000095017024106974/ownership.xml","form_type":"4"}},{"id":1406423,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-16T20:49:03.000Z","date":"2024-09-12","kind":"sale","planned":false,"acquired":false,"shares":5212,"price":4.4727,"value":23311.7124,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.37 to $4.62, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc (\"Mereo\"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4."}],"balance_after":89567,"source":{"system":"sec-edgar","filing":"0000950170-24-106974","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000095017024106974/ownership.xml","form_type":"4"}},{"id":1407440,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Performance Based Restricted Stock Unit","published_at":"2024-09-13T16:49:18.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":false,"shares":46000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2024-09-11","expiration_date":"2025-01-25","underlying":"American Depository Shares","underlying_shares":46000},"source":{"system":"sec-edgar","filing":"0000950170-24-106418","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000095017024106418/ownership.xml","form_type":"4"}},{"id":1407439,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-13T16:49:18.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":true,"shares":46000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents performance-based restricted stock unit earned under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on September 11, 2024 based on satisfaction of ADS price threshold values over a two year performance period."}],"balance_after":94779,"source":{"system":"sec-edgar","filing":"0000950170-24-106418","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000095017024106418/ownership.xml","form_type":"4"}},{"id":1467972,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-27T16:15:33.000Z","date":"2024-06-26","kind":"sale","planned":false,"acquired":false,"shares":16808,"price":3.3932,"value":57032.9056,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.28 to $3.51, inclusive."}],"balance_after":48779,"source":{"system":"sec-edgar","filing":"0000950170-24-078468","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000095017024078468/ownership.xml","form_type":"4"}},{"id":1467971,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-27T16:15:33.000Z","date":"2024-06-25","kind":"sale","planned":false,"acquired":false,"shares":7416,"price":3.6939,"value":27393.9624,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.60 to $3.805, inclusive. The Reporting\nPerson undertakes to provide to Mereo BioPharma Group plc (\"Mereo\"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full\ninformation regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4."}],"balance_after":65587,"source":{"system":"sec-edgar","filing":"0000950170-24-078468","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000095017024078468/ownership.xml","form_type":"4"}},{"id":1469344,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Performance Based Restricted Stock Unit","published_at":"2024-06-25T18:21:23.000Z","date":"2024-06-21","kind":"exercise","planned":false,"acquired":true,"shares":69000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":46000,"derivative":{"exercise_price":0,"exercise_date":"2024-06-21","expiration_date":"2025-01-25","underlying":"American Depository Shares","underlying_shares":69000},"source":{"system":"sec-edgar","filing":"0000950170-24-077487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000095017024077487/ownership.xml","form_type":"4"}},{"id":1469343,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-25T18:21:23.000Z","date":"2024-06-21","kind":"exercise","planned":false,"acquired":true,"shares":69000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents performance-based restricted stock unit (\"PSU\") earned under the issuer's 2019 Employee Incentive Plan (the \"Plan\") that vested on June 21, 2024 based on satisfaction of ADS price threshold values over a two year performance period (expiring on January 1, 2025)."}],"balance_after":73003,"source":{"system":"sec-edgar","filing":"0000950170-24-077487","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000095017024077487/ownership.xml","form_type":"4"}},{"id":1669330,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Share Options (Right to buy)","published_at":"2024-01-26T16:15:11.000Z","date":"2024-01-25","kind":"grant","planned":false,"acquired":true,"shares":137000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on January 25, 2025, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":137000,"derivative":{"exercise_price":3.36,"expiration_date":"2034-01-25","underlying":"American Depository Shares","underlying_shares":137000},"source":{"system":"sec-edgar","filing":"0000950170-24-007936","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000095017024007936/ownership.xml","form_type":"4"}},{"id":3551028,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-04-23T16:15:31.000Z","date":"2019-04-23","kind":"other","acquired":false,"shares":142534,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC (\"Mereo\"), Mereo US Holdings Inc., Mereo Mergerco One Inc. (\"Merger Sub\") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the \"Merger\"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the \"Merger Consideration\") for each share of the Issuer's stock that they own."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-19-010987","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000089924319010987/doc4.xml","form_type":"4"}},{"id":3660055,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-02-13T19:51:27.000Z","date":"2018-08-06","kind":"gift","acquired":true,"shares":11793,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by John Allan Lewicki and Jenniffer Joan Lewicki, Trustees of the Lewicki Family Trust dated December 6, 2000."}],"balance_after":111181,"source":{"system":"sec-edgar","filing":"0001567619-19-003877","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000156761919003877/doc1.xml","form_type":"5"}},{"id":3660054,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-02-13T19:51:27.000Z","date":"2018-08-06","kind":"gift","acquired":false,"shares":11793,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 36,250 RSUs. The Reporting Person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof."}],"balance_after":44173,"source":{"system":"sec-edgar","filing":"0001567619-19-003877","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000156761919003877/doc1.xml","form_type":"5"}},{"id":3792325,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-11T18:55:39.000Z","date":"2018-10-10","kind":"sale","acquired":false,"shares":1156,"price":2.01,"value":2323.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock units (\"RSU\") award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades in prices ranging from $2.0100 to $2.0301, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 36,250 RSUs. The Reporting Person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof."}],"balance_after":55966,"source":{"system":"sec-edgar","filing":"0001567619-18-004054","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000156761918004054/doc1.xml","form_type":"4"}},{"id":3793374,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-10-10T19:40:23.000Z","date":"2018-10-09","kind":"sale","acquired":false,"shares":2296,"price":2.1289,"value":4887.9544,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock units (\"RSU\") award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades in prices ranging from $2.1082 to $2.1289, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 39,375 RSUs. The Reporting Person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 2,000 shares acquired under the Issuer's Employee Stock Purchase Plan on February 28, 2018 and 2,000 shares acquired under the Issuer's Employee Stock Purchase Plan on August 31, 2018."}],"balance_after":57122,"source":{"system":"sec-edgar","filing":"0001567619-18-003956","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000156761918003956/doc1.xml","form_type":"4"}},{"id":3956059,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-04-26T18:13:11.000Z","date":"2018-04-24","kind":"sale","acquired":false,"shares":4557,"price":2.6777,"value":12202.2789,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock units (\"RSU\") award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades in prices ranging from $2.612 to $2.682771, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 45,625 RSUs. The Reporting Person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof."}],"balance_after":55418,"source":{"system":"sec-edgar","filing":"0001140361-18-019833","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036118019833/doc1.xml","form_type":"4"}},{"id":3989322,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-19T18:42:20.000Z","date":"2018-03-16","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of March 16, 2018, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":125000,"derivative":{"exercise_price":2.98,"expiration_date":"2028-03-15","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001140361-18-014120","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036118014120/doc1.xml","form_type":"4"}},{"id":4036755,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-23T18:39:47.000Z","date":"2018-02-21","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of January 31, 2018, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":125000,"derivative":{"exercise_price":2.23,"expiration_date":"2028-02-20","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001140361-18-009950","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036118009950/doc1.xml","form_type":"4"}},{"id":4073577,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-02-06T19:57:16.000Z","date":"2017-05-10","kind":"gift","acquired":true,"shares":10437,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by John Allan Lewicki and Jenniffer Joan Lewicki, Trustees of the Lewicki Family Trust dated December 6, 2000."}],"balance_after":99388,"source":{"system":"sec-edgar","filing":"0001140361-18-005412","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036118005412/doc1.xml","form_type":"5"}},{"id":4073576,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-02-06T19:57:16.000Z","date":"2017-05-10","kind":"gift","acquired":false,"shares":10437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 56,875 RSUs. The Reporting Person is entitled to receive one (1) share of common stock of the issuer for  each one (1) RSU upon the vesting thereof."}],"balance_after":59975,"source":{"system":"sec-edgar","filing":"0001140361-18-005412","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036118005412/doc1.xml","form_type":"5"}},{"id":4104094,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-08T19:08:41.000Z","date":"2018-01-04","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":3.98,"expiration_date":"2028-01-03","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001140361-18-001274","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036118001274/doc1.xml","form_type":"4"}},{"id":4187351,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Common Stock","published_at":"2017-10-12T18:35:01.000Z","date":"2017-10-10","kind":"sale","acquired":false,"shares":1202,"price":4.2418,"value":5098.6436,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit (\"RSU\") award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 56,875 RSUs. The Reporting Person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof."}],"balance_after":70412,"source":{"system":"sec-edgar","filing":"0001140361-17-038566","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036117038566/doc1.xml","form_type":"4"}},{"id":4187350,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Common Stock","published_at":"2017-10-12T18:35:01.000Z","date":"2017-10-10","kind":"sale","acquired":false,"shares":46,"price":4.2604,"value":195.9784,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit (\"RSU\") award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 56,875 RSUs. The Reporting Person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof."}],"balance_after":71614,"source":{"system":"sec-edgar","filing":"0001140361-17-038566","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036117038566/doc1.xml","form_type":"4"}},{"id":4188903,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-10-10T19:28:12.000Z","date":"2017-10-07","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":50000,"derivative":{"exercise_price":4.36,"expiration_date":"2027-10-06","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001140361-17-038098","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036117038098/doc1.xml","form_type":"4"}},{"id":4188902,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Common Stock","published_at":"2017-10-10T19:28:12.000Z","date":"2017-10-07","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units (\"RSUs\"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) 60,000 RSUs and (ii) 1,223 shares acquired under the Issuer's Employee Stock Purchase Plan on August 31, 2017."}],"balance_after":71660,"source":{"system":"sec-edgar","filing":"0001140361-17-038098","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036117038098/doc1.xml","form_type":"4"}},{"id":4345501,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-04-25T18:11:20.000Z","date":"2017-04-23","kind":"grant","acquired":true,"shares":67500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":67500,"derivative":{"exercise_price":3.73,"expiration_date":"2027-04-22","underlying":"Common Stock","underlying_shares":67500},"source":{"system":"sec-edgar","filing":"0001140361-17-016765","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036117016765/doc1.xml","form_type":"4"}},{"id":4345500,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Common Stock","published_at":"2017-04-25T18:11:20.000Z","date":"2017-04-23","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units (\"RSUs\"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 35,000 RSUs."}],"balance_after":45437,"source":{"system":"sec-edgar","filing":"0001140361-17-016765","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036117016765/doc1.xml","form_type":"4"}},{"id":4358073,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Common Stock","published_at":"2017-04-05T19:56:04.000Z","date":"2017-04-04","kind":"sale","acquired":false,"shares":5711,"price":9.0582,"value":51731.3802,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 12,500 restricted stock units (\"RSUs\").  The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,191 shares acquired under the Issuer's Employee Stock Purchase Plan on February 28, 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Reflects an aggregate of 4,136 shares the Reporting Person previously transferred to his family trust."}],"balance_after":22937,"source":{"system":"sec-edgar","filing":"0001140361-17-015056","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036117015056/doc1.xml","form_type":"4"}},{"id":4358072,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Common Stock","published_at":"2017-04-05T19:56:04.000Z","date":"2017-04-04","kind":"sale","acquired":false,"shares":43,"price":8.8671,"value":381.2853,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 12,500 restricted stock units (\"RSUs\").  The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,191 shares acquired under the Issuer's Employee Stock Purchase Plan on February 28, 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Reflects an aggregate of 4,136 shares the Reporting Person previously transferred to his family trust."}],"balance_after":28648,"source":{"system":"sec-edgar","filing":"0001140361-17-015056","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036117015056/doc1.xml","form_type":"4"}},{"id":4498244,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-05T19:11:18.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":65000,"derivative":{"exercise_price":7.66,"expiration_date":"2027-01-02","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001140361-17-000855","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036117000855/doc1.xml","form_type":"4"}},{"id":4498243,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-05T19:11:18.000Z","date":"2017-01-03","kind":"exercise","acquired":false,"shares":9175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 16, 2016."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option is fully vested and exercisable, subject to an annual limitation of 175,438 shares that can be issued to a single grantee upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan."}],"balance_after":0,"derivative":{"exercise_price":1.43,"expiration_date":"2017-01-11","underlying":"Common Stock","underlying_shares":9175},"source":{"system":"sec-edgar","filing":"0001140361-17-000855","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036117000855/doc1.xml","form_type":"4"}},{"id":4498242,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Common Stock","published_at":"2017-01-05T19:11:18.000Z","date":"2017-01-03","kind":"sale","acquired":false,"shares":9175,"price":7.6343,"value":70044.7025,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 16, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades in prices ranging from $7.56 to $7.825, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 27,500 restricted stock units.  The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit."}],"balance_after":31636,"source":{"system":"sec-edgar","filing":"0001140361-17-000855","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036117000855/doc1.xml","form_type":"4"}},{"id":4498241,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Common Stock","published_at":"2017-01-05T19:11:18.000Z","date":"2017-01-03","kind":"exercise","acquired":true,"shares":9175,"price":1.43,"value":13120.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 16, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 27,500 restricted stock units.  The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit."}],"balance_after":40811,"source":{"system":"sec-edgar","filing":"0001140361-17-000855","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036117000855/doc1.xml","form_type":"4"}},{"id":4581441,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Development"}}],"security":"Common Stock","published_at":"2016-10-11T21:44:17.000Z","date":"2016-10-09","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units (\"RSUs\"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 27,500 restricted stock units and 1,298 shares acquired under the Issuer's Employee Stock Purchase Plan on February 29, 2016."}],"balance_after":31636,"source":{"system":"sec-edgar","filing":"0001140361-16-082543","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036116082543/doc1.xml","form_type":"4"}}]}